BMO Capital on Novo Nordisk (NVO): 'given that Amycretin is a peptide we would like to hear more from Novo on manufacturing, a potential point of differentiation for the small molecule assets'
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $160.00 price target on Novo Nordisk (NYSE: NVO).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
